WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that it has received positive initial results from the animal trials of its drug candidates for the treatment of epidemic keratoconjunctivitis (EKC), a severe viral infection of the eye. Evidence of significant effectiveness was clinically observed in treated infected eyes.
